The Cure SMA educational campaign is designed to equip parents and healthcare professionals with the tools needed to recognize motor delays in spinal muscular atrophy (SMA) patients early, allowing infants and children to receive potentially life-saving treatment. Called SMArt Moves, the program cites the fact that Spinraza and…
News
Damage That Marks SMA Type 3 and 4 Linked to Atrophy in Neck Area of Spinal Cord, Study Reports
Later-onset forms of spinal muscular atrophy (SMA) are linked to extensive atrophy in the cervical spinal cord, particularly in gray matter of the vertebrae, that may begin long before symptoms are evident, researchers report. The study, “The spinal and cerebral profile of adult spinal-muscular atrophy: A multimodal imaging study,”…
Researchers at Stanford University School of Medicine found that a molecule called Activating Signal Cointegrator 1 (ASC-1) acts “a central hub” for proteins involved in amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), suggesting that both disorders “are more intimately tied to one another than previously…
Treatment of spinal muscular atrophy (SMA) with Spinraza (nusinersen) through the spinal canal is feasible and leads to high patient compliance as long as it’s done under the supervision of an experienced multidisciplinary team, according to a single-center study in Italy. The study, “Intrathecal nusinersen…
The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis’ Biological License Application (BLA) asking that Zolgensma (onasemnogene abeparvovec-xxxx) — previously called AVXS-101 — be approved as a gene therapy for spinal muscular atrophy (SMA) type 1. Its request is reported to specifically cover intravenous…
Administration of Spinraza (nusinersen) directly into the spinal canal is feasible and well-tolerated by adults with spinal muscular atrophy (SMA) type 2 or 3. Still, such treatment can be challenging for SMA type 2 patients and those who have had spinal fusion, a study shows. The study,…
Scholar Rock Announces Additional Preclinical Data Supporting SRK-015 as Potential SMA Treatment
Scholar Rock has announced the publication of new preclinical data supporting the potential therapeutic value of its experimental candidate therapy, SRK-015, in improving muscle function and strength in patients with spinal muscular atrophy (SMA). The study, “Specific inhibition of myostatin activation is beneficial in mouse models of…
The use of a robotic arm controlled by electrical impulses in the arm muscles may increase the independence of paralyzed spinal muscular atrophy (SMA) patients, according to a recent case report. The case report, “Functional Tasks Performed by People with Severe Muscular Atrophy Using an sEMG Controlled…
Danyelle Sun, a Milwaukee mother of two children with spinal muscular atrophy (SMA), says Biogen’s Spinraza (nusinersen) has rescued both her kids from potentially lifelong disabilities. Sun, 35, is the Wisconsin state ambassador for NORD, the National Organization for Rare Diseases. Her 7-year-old daughter, Ruby, has SMA type 3,…
Researchers from the University of North Carolina have described 14 different fruit fly models that mimic all the types of spinal muscular atrophy (SMA) seen in patients. These include SMA type 4, also known as adult-onset SMA, which has been particularly hard to replicate in other animal models…
Recent Posts
- The transition to adult healthcare brings both fear and gratitude
- Early nerve-muscle connection flaws set stage for SMA damage
- When fate tested our theory that things happen for a reason
- Evrysdi boosts motor function, quality of life in Asian SMA patients
- Learning to resolve conflict with friends who are also caregivers
